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Providing a Lens Into the
Interconnected Diseases of the Heart and BrainValentin Fuster, MD, PHDM any philosophers have explored the inter-connectedness between the brain and theheart; yet, technological advances in im-
aging, increased physiological understanding, and a
greater appreciation of optimal medical therapy
have allowed cardiovascular researchers and clini-
cians to better comprehend how to assess and treat
the vulnerable patient who experiences a systemic
disease process across the vasculatures of the heart
and brain.
Over the past 10 years, atherosclerosis research has
shifted from a local outlook, which utilized invasive
imaging techniques to assess vulnerable plaque and
high-risk plaques, to a systemic process, focusing
on the vulnerable patient and the burden of dis-
ease, which uses various diagnostic and prognostic
methods, including biomarkers and optimal medical
therapies (1). Because atherosclerosis is a systemic
process, it is intuitive that assessing disease at multi-
ple, rather than single, vascular sites may provide
greater insight on the overall burden and risk associ-
ated with subclinical atherosclerosis (2). As a point of
demonstration, in 2 recent bioimaging studies we
assessed approximately 10,000 asymptomatic adults
>40 years of age, using multimodality vascular imag-
ing of the coronary arteries with electron-beam
computed tomography for calciﬁcation and of the ca-
rotid arteries with 3-dimensional ultrasound was per-
formed (2,3). We found that subclinical atherosclerosis
was highly prevalent, detectable in both the coronary
and carotid vascular territories in close to 60% of par-
ticipants (2,3). Thus, we concluded that incorporating
detection of subclinical atherosclerosis, irrespective of
anatomic territory, in addition to cardiovascular risk. Wiener Cardiovascular Institute, Icahn
inai, New York, New York.factors could be considered in the future for patient
management decisions.
As the investigational and the clinical communities
have been seeking to better understand the vulner-
able patient, it has been increasingly recognized that
degenerative brain disease (DBD) is intimately linked
to the vasculature and overall burden of disease, on
which I have just commented (4–6). This DBD axis is
perceptible across a very broad spectrum of disease,
from macrovascular large vessel coronary or carotid
diseases leading to myocardial infarction or stroke,
to microvascular small vessel changes causing
dementia (4). Overall, the critical importance of
subclinical macrovascular and microvascular diseases
with respect to brain, heart, kidney, and other organ
function, when examined through the lens of the
vulnerable patient, is that they will contribute to the
continued progress in ﬁghting these diseases (4).
Thus, we must make a transition from primarily
considering the coronary vessels to looking at the
entire patient in terms of systemic cardiovascular
disease (4).
Furthermore, within the context of the burden of
disease/DBD axis, one of the most signiﬁcant risk
factors for the vulnerable patient is aging. And, as our
population becomes increasingly older, the preva-
lence of these interconnected disease states will
proliferate, in particular DBD. We have already
witnessed a tremendous rise in the diagnosis of Alz-
heimer’s disease—the incidence of which doubles
every 5 years after 65 years of age, with the diagnosis
of 1,275 new cases per year per 100,000 persons older
than 65 years of age (7). The prevalence is expected to
approach 13.2 to 16.0 million cases in the United
States by the midcentury (8). However, this increase
in DBD cannot be viewed in a vacuum, because
several observations have shown that ischemic
microvascular disease affects 60 to 90% of patients
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1078with Alzheimer’s disease (9). Additional research has
shown that hypertension and diabetes lead to a
decrease in vascular reserve capacity and can cause
microvascular disease, stroke, cognitive decline, and
dementia (10). Factors other than perfusion, such as
genetic predisposition, autonomic failure, and neu-
rodegeneration, also contribute to the progression of
Alzheimer’s disease and dementia (10).
However, as we continue to learn the mecha-
nisms behind the connection between cardiovascu-
lar risk factors and cognitive function, the CARDIA
(Coronary Artery Risk Development in Young
Adults) study demonstrated that cumulative expo-
sure to cardiovascular risk factors from early to
middle adulthood, especially above recommended
guidelines, was associated with worse cognition
in midlife (11). In this prospective study of 3,381
adults, the primary predictor was 25-year cumula-
tive exposure estimated by areas under the curve
for resting systolic and diastolic blood pressures,
fasting blood glucose, and total cholesterol (11). The
authors concluded that their ﬁndings warrant more
aggressive treatment of cardiovascular risk factors
earlier in life.
Thus, FINGER (Finnish Geriatric Intervention Study
to Prevent Cognitive Impairment and Disability)randomly assigned 2,654 individuals with cognitive
dysfunction and cardiovascular risk factors—1,260
to the intervention group (n ¼ 631) or control
group (n ¼ 629) (12). The authors randomly assigned
participants in a 1:1 ratio to a 2-year multidomain
intervention, including diet, exercise, cognitive
training, and vascular risk modiﬁcation, or a con-
trol group, which consisted of general health
advice. Of importance, ﬁndings suggest that a multi-
domain intervention could improve or maintain
cognitive functioning in at-risk elderly people from
the general population.
In summary, as we are being challenged to not
simply focus on treating diseases once they manifest,
but rather address risk factors that contribute to
those diseases, here is an opportunity where we can
investigate, diagnose, and treat an at-risk patient—a
vulnerable patient, who could beneﬁt from lifestyle
modiﬁcations before clinical manifestations affect the
heart and the brain.
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